Table 2 Details of 1512 women who received MgSO4 for fetal NP administration and adverse effects during MAG-CP (N (%) women unless otherwise specified)
N (%) or median [IQR] | |
|---|---|
Gestational age at time of MgSO4 therapy (week) | 27.1 [25.6, 28.4] |
Cervical dilatation at time of therapy (cm) | 3 [1.5,4.5] |
Cervical dilatation ≥ 4 cm | 570 (37.7%) |
Cervical dilatation ≥ 4 cm among women with PTL | 384/728 (52.7%) |
Missing/unknown | 227 (15.0%) |
N treatment courses/woman | 1 [1,1] |
Received more than one course | 110 (7.3%) |
Received only loading dose | 222 (14.7%) |
Received only maintenance dose | 44 (2.9%) |
Received both loading and maintenance doses | 1246 (82.4%) |
Loading dose details | |
Route of administration | |
IV only | 1464 (96.8%) |
IM only | 2 (0.1%) |
Initial dose (g) | 4 [4,4] |
Duration of therapy (min) | 25 [20, 30] |
Missing | 95 (6.5%) |
Adverse maternal effects (one/more) | 6 (0.4%) |
Maternal hypotension | 5 (0.3%) |
Respiratory depression | 0 |
Pulmonary oedema | 1 (0.1%) |
Loading dose stopped early | 45 (3.1%) |
Stopped because woman delivered | 38 (2.6%) |
Stopped because patient refused treatment or further treatment | 1 (0.1%) |
Stopped because of maternal side effects | 0 |
Stopped because woman was no longer in imminent preterm birth | 1 (0.1%) |
Other* | 4 (0.3%) |
Calcium gluconate administered | 0 |
Maintenance dose details | |
Route of administration | |
IV only | 1290 (85.3%) |
IM only | 0 |
Initial dose (g/h) | 1 [1,1] |
Duration of therapy (h) | 7.4 [3.1, 17.5] |
Adverse maternal effects (one/more) | 13 (0.9%) |
Maternal hypotension | 3 (0.2%) |
Respiratory depression | 0 |
Pulmonary oedema | 10 (0.7%) |
Reasons for stopping maintenance dose | |
Stopped because woman delivered | 738 (57.2%) |
Stopped because 24 h of therapy had been administered | 81 (6.3%) |
Stopped because woman was no longer in imminent preterm birth | 163 (12.6%) |
Stopped because of maternal side effects | 0 |
Other† | 29 (2.2%) |
No reason indicated or missing | 279 (21.6%) |
Calcium gluconate administered | 1 (0.1%) |